Novartis today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation for 177Lu-PSMA-617, an investigational radioligand therapy (RLT) for the treatment of adult patients with prostate-specific membrane antigen ...